In a drug discovery career spanning more than two decades, Alex Lugovskoy has seen a lot of antibodies come and go. The vast majority of them work by inhibiting a cellular function. Lugovskoy, now the ...

Backed by more than a dozen prominent investors, the startup is advancing into human testing a drug it believes capable of treating two disparate conditions, one of which is the target of Merck’s fast ...

Joel Levinson was in his second year of architecture studies at the University of Pennsylvania when he overheard two students speaking as if they were up to no good. These being fellow building buffs, ...

Diagonal Therapeutics is taking shape, launching with $128 million and backed by the likes of BVF Partners, Atlas Venture and RA Capital to develop a pipeline of antibody agonists. The company will ...